GOWEN MAXINE — SEC Form 4 filings
SEC reporting owner CIK 1280044. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-08.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-05-09 to 2026-06-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | Director | 4 | — | — | 12 |
| Merus N.V. (MRUS) | Director | 3 | — | — | 8 |
| Passage BIO, Inc. (PASG) | Director | 3 | — | — | 3 |
Form 4 filings — GOWEN MAXINE
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-08 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Passage BIO, Inc. (PASG) | Grant/award (A): 10,539 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Merus N.V. (MRUS) | Disposition to issuer (D): 13,193 (derivative) @ $0 · Disposition to issuer (D): 8,844 (derivative) @ $0 · Disposition to issuer (D): 14,414 (derivative) @ $0 · Disposition to issuer (D): 16,604 (derivative) @ $0 · Disposition to issuer (D): 12,240 (derivative) @ $0 · Disposition to issuer (D): 7,957 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Passage BIO, Inc. (PASG) | Grant/award (A): 201,857 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Merus N.V. (MRUS) | Grant/award (A): 13,193 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Grant/award (A): 15,750 (derivative) @ $0 · Grant/award (A): 4,793 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 4,660 · Option exercise (M): 4,660 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | Passage BIO, Inc. (PASG) | Grant/award (A): 47,693 (derivative) @ $0 | EDGAR |
| 2024-05-09 | 4 | Merus N.V. (MRUS) | Grant/award (A): 8,844 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1280044 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →